单位:[1]University of Oklahoma Health Sciences Center[2]Oklahoma Medical Research Foundation[3]Helmholtz Munich,Germany[4]University of Iowa[5]Netherlands Cancer Institute,Amsterdam[6]University of Chicago, IL[7]Ann & Robert H. Lurie Children’s Hospital of Chicago, IL[8]Northwestern University Feinberg School of Medicine, Chicago, IL[9]Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院
Tetraspanin CD151 is highly expressed in endothelia and reinforces cell adhesion, but its role in vascular inflammation remains largely unknown.In vitro molecular and cellular biological analyses on genetically modified endothelial cells, in vivo vascular biological analyses on genetically engineered mouse models, and in silico systems biology and bioinformatics analyses on CD151-related events.Endothelial ablation of Cd151 leads to pulmonary and cardiac inflammation, severe sepsis, and perilous COVID-19, and endothelial CD151 becomes downregulated in inflammation. Mechanistically, CD151 restrains endothelial release of proinflammatory molecules for less leukocyte infiltration. At the subcellular level, CD151 determines the integrity of multivesicular bodies/lysosomes and confines the production of exosomes that carry cytokines such as ANGPT2 (angiopoietin-2) and proteases such as cathepsin-D. At the molecular level, CD151 docks VCP (valosin-containing protein)/p97, which controls protein quality via mediating deubiquitination for proteolytic degradation, onto endolysosomes to facilitate VCP/p97 function. At the endolysosome membrane, CD151 links VCP/p97 to (1) IFITM3, which regulates multivesicular body functions, to restrain IFITM3-mediated exosomal sorting, and (2) V-ATPase, which dictates endolysosome pH, to support functional assembly of V-ATPase.Distinct from its canonical function in strengthening cell adhesion at cell surface, CD151 maintains endolysosome function by sustaining VCP/p97-mediated protein unfolding and turnover. By supporting protein quality control and protein degradation, CD151 prevents proteins from (1) buildup in endolysosomes and (2) discharge through exosomes, to limit vascular inflammation. Also, our study conceptualizes that balance between degradation and discharge of proteins in endothelial cells determines vascular information. Thus, the IFITM3/V-ATPase-tetraspanin-VCP/p97 complexes on endolysosome, as a protein quality control and inflammation-inhibitory machinery, could be beneficial for therapeutic intervention against vascular inflammation.
基金:
This work was supported by the National Institutes of Health (NIH) grants
HL132553, HL137819, and GM135547 and American Heart Association
grants 13GRNT17040028 and 15GRNT25700426 to X.A. Zhang. The core
facilities were supported by NIH grants P20GM103639 and P30CA225520.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|1 区医学
小类|1 区心脏和心血管系统1 区血液学1 区外周血管病
最新[2025]版:
大类|1 区医学
小类|1 区心脏和心血管系统1 区血液学1 区外周血管病
第一作者:
第一作者单位:[1]University of Oklahoma Health Sciences Center
通讯作者:
推荐引用方式(GB/T 7714):
Junxiong Chen,Yingjun Ding,Chao Jiang,et al.CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation[J].Circulation Research.2024,doi:10.1161/CIRCRESAHA.123.323190.
APA:
Junxiong Chen,Yingjun Ding,Chao Jiang,Rongmei Qu,Jonathan D. Wren...&Xin A. Zhang.(2024).CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation.Circulation Research,,
MLA:
Junxiong Chen,et al."CD151 Maintains Endolysosomal Protein Quality to Inhibit Vascular Inflammation".Circulation Research .(2024)